1. Advances in Peanut Allergy

3. This program will include a discussion of investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Pathophysiology of Peanut Allergy

5. Peanut Allergy Prevalence and Natural Course

6. Peanut Allergy Burden

7. Allergy vs Tolerance

8. LEAP Study Design

9. LEAP Prevalence of Peanut Allergy at 60 Months of Age

10. LEAP-On Prevalence of Peanut Allergy 12 Months After Avoidance

11. LEAP and LEAP-On Key Findings

12. NIAID Recommendations For Risk Reduction of Peanut Allergy

13. Risk Reduction for Peanut Protein Exposure

14. Thresholds for Peanut Allergy

15. Factors That Can Influence Threshold Dose

16. Significance of Threshold Dose

17. Exposure Dose Calculation

18. Peanut Immunotherapies in Development

19. QRA Modeling Clinical Relevance of Higher Threshold

20. QRA Modeling Take Home Messages

21. Peanut Allergen Immunotherapy

22. Peanut Allergy Current Management Strategies

23. Allergen Immunotherapy Premise

24. Desensitization vs Tolerance vs Sustained Unresponsiveness in Food Allergy Literature

25. Immunotherapies in Development

26. PALISADE Phase 3 Trial ITT Efficacy Results

27. PALISADE Safety Results

28. PEPITES Phase 3 Trial Preliminary Efficacy Results

29. PEPITES Preliminary Safety Results

30. OIT Limitations and Advantages

31. EPIT Limitations and Advantages

32. SLIT Limitations and Advantages

33. Summary

34. Abbreviations